Heron Therapeutics (NASDAQ:HRTX – Get Free Report) and Vireo Growth (OTCMKTS:VREOD – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.
Analyst Ratings
This is a summary of current ratings and target prices for Heron Therapeutics and Vireo Growth, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Heron Therapeutics | 1 | 3 | 1 | 0 | 2.00 |
| Vireo Growth | 1 | 0 | 0 | 0 | 1.00 |
Heron Therapeutics presently has a consensus target price of $2.00, suggesting a potential upside of 481.56%. Given Heron Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Heron Therapeutics is more favorable than Vireo Growth.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Heron Therapeutics | -22.52% | -293.02% | -10.00% |
| Vireo Growth | -23.37% | -19.76% | -7.15% |
Earnings & Valuation
This table compares Heron Therapeutics and Vireo Growth”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Heron Therapeutics | $154.90 million | 0.42 | -$20.19 million | ($0.19) | -1.81 |
| Vireo Growth | $268.77 million | 1.68 | -$68.11 million | ($3.30) | -3.02 |
Heron Therapeutics has higher earnings, but lower revenue than Vireo Growth. Vireo Growth is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
80.0% of Heron Therapeutics shares are held by institutional investors. 6.1% of Heron Therapeutics shares are held by insiders. Comparatively, 3.8% of Vireo Growth shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Volatility and Risk
Heron Therapeutics has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500. Comparatively, Vireo Growth has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500.
Summary
Heron Therapeutics beats Vireo Growth on 9 of the 14 factors compared between the two stocks.
About Heron Therapeutics
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
About Vireo Growth
Goodness Growth Holdings, Inc. operates as a cannabis company in the United States. The company cultivates, processes, and distributes medical and adult-use cannabis products. It sells cannabis products through its network of Green Goods and other Goodness Growth branded retail dispensaries and third-party dispensaries in Maryland, Minnesota, and New York. The company was formerly known as Vireo Health International Inc. and changed its name to Goodness Growth Holdings, Inc. in June 2021. Goodness Growth Holdings, Inc. is headquartered in Minneapolis, Minnesota.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
